{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:49:32Z","timestamp":1792154972805,"version":"4.4.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The ADRIATIC trial has established durvalumab as a new standard of care for limited-stage small-cell lung cancer (LS-SCLC) by showing significant survival benefits after chemoradiotherapy (CRT). In this study, the cost-effectiveness of this regimen was evaluated from Chinese and U.S. payer perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A partitioned survival model was used to estimate the lifetime costs and quality-adjusted life-years (QALYs) of patients receiving durvalumab compared with placebo after CRT. Data were sourced from the ADRIATIC trial. Outcomes included incremental cost-effectiveness ratios (ICERs), with uncertainty assessed via deterministic and probabilistic sensitivity analyses (PSAs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the base-case analysis for China, the ICER was $136,209.12 per QALY, which exceeds the $40,334.05 willingness-to-pay (WTP) threshold. For the U.S., the ICER was $214,184.71 per QALY, which is higher than the $150,000 WTP threshold. However, under the Chinese patient assistance program (PAP), the ICER decreased to $18,495.23 per QALY, making it cost-effective. Subgroup analysis revealed cost-effectiveness only in the U.S. carboplatin subgroup (ICER: $139,909.75 per QALY). PSA confirmed a low probability of cost-effectiveness (0\u20135.33%) in base-case scenarios, which increased to 99.93% under the Chinese PAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>At present, durvalumab consolidation therapy is not considered cost-effective for LS-SCLC in either country at the current WTP threshold. However, the Chinese PAP renders it a cost-effective option, highlighting the critical role of pricing and patient access programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_336_26","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:00:32Z","timestamp":1790766032000},"page":"674-681","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of durvalumab consolidation therapy in limited-stage small-cell lung cancer: A Chinese and U.S. payer perspective analysis"],"prefix":"10.4103","volume":"22","author":[{"given":"Chengjun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Social Medicine and Health Management, School of Public Health, Shandong University, Jinan, Shandong, China"},{"name":"NHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Song","sequence":"additional","affiliation":[{"name":"Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfei","family":"Liu","sequence":"additional","affiliation":[{"name":"Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University (Qingdao), Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"R1-20261016","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"100077","DOI":"10.1016\/j.engmed.2025.100077","article-title":"GA-AGN: A generative adversarial network and attention gated network model for enhanced lung cancer detection using chest CT scans","volume":"2","author":"Joseph","year":"2025","journal-title":"EngMedicine"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung cancer statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cac2.12627","article-title":"Cancer situation in China: An analysis based on the global epidemiological data released in 2024","volume":"45","author":"Diao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: A review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4103\/jcrt.jcrt_251_25","article-title":"Precision treatment patterns and prognostic analysis: A retrospective study of small-cell lung cancer","volume":"21","author":"Wang","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R10-20261016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.21.01639","article-title":"Radiation and systemic therapy for limited-stage small-cell lung cancer","volume":"40","author":"Bogart","year":"2022","journal-title":"J Clin Oncol"},{"key":"R11-20261016","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): An open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"R12-20261016","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41568-025-00803-0","article-title":"Challenges of small cell lung cancer heterogeneity and phenotypic plasticity","volume":"25","author":"Simpson","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"R13-20261016","first-page":"620","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R14-20261016","doi-asserted-by":"crossref","first-page":"10732748251334434","DOI":"10.1177\/10732748251334434","article-title":"Immunotherapy for limited-stage small cell lung cancer: Innovative treatments and future perspectives","volume":"32","author":"Jin","year":"2025","journal-title":"Cancer Control"},{"key":"R15-20261016","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s43018-025-00996-1","article-title":"Advancing therapeutics in small-cell lung cancer","volume":"6","author":"Thomas","year":"2025","journal-title":"Nat Cancer"},{"key":"R16-20261016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","article-title":"Durvalumab: A review in extensive-stage SCLC","volume":"16","author":"Al-Salama","year":"2021","journal-title":"Target Oncol"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/jcrt.jcrt_964_24","article-title":"Efficacy and safety of immune checkpoint inhibitors combined with radiotherapy in non-small-cell lung cancer: A meta-analysis with potential clinical predictors","volume":"21","author":"Dai","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R18-20261016","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.cllc.2019.12.006","article-title":"Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without Tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: The ADRIATIC study","volume":"21","author":"Senan","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"R20-20261016","first-page":"1","article-title":"The ADRIATIC study: Revolutionizing the standard treatment paradigm for concurrent chemoradiotherapy in limited-stage small cell lung cancer","volume":"5","author":"Pan","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s43018-025-00992-5","article-title":"The current and emerging immunotherapy paradigm in small-cell lung cancer","volume":"6","author":"Qin","year":"2025","journal-title":"Nat Cancer"},{"key":"R22-20261016","first-page":"1348","article-title":"ADRIATIC: When face value is enough","volume":"5","author":"Addeo","year":"2024","journal-title":"Med (New York, NY)"},{"key":"R23-20261016","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2174\/0125899775394503250626070441","article-title":"The Pharmacoeconomics and its evaluation in enhancing the Indian healthcare system","volume":"18","author":"Agarwal","year":"2026","journal-title":"Curr Drug Res Rev"},{"key":"R24-20261016","first-page":"3736","volume":"104","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R27-20261016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"R28-20261016","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s11096-024-01802-1","article-title":"Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China","volume":"46","author":"Lang","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"R30-20261016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v095.i14","article-title":"survHE: Survival analysis for health economic evaluation and cost-effectiveness modeling","volume":"95","author":"Baio","year":"2020","journal-title":"J Stat Softw"},{"key":"R33-20261016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14737167.2021.1888717","article-title":"Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China","volume":"22","author":"Liu","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R34-20261016","doi-asserted-by":"crossref","first-page":"e37836","DOI":"10.1097\/MD.0000000000037836","article-title":"Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer","volume":"103","author":"Meng","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R35-20261016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy\u2014results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"R36-20261016","doi-asserted-by":"crossref","first-page":"LBA8005","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8005","article-title":"Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC)","volume":"43","author":"Gronberg","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_336_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:01:38Z","timestamp":1792152098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_336_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_336_26","relation":{},"ISSN":["1998-4138","0973-1482"],"issn-type":[{"value":"1998-4138","type":"print"},{"value":"0973-1482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}